Proficio Capital Partners LLC Raises Holdings in Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4,418.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 147,360 shares of the company's stock after purchasing an additional 144,099 shares during the period. Proficio Capital Partners LLC's holdings in Moderna were worth $6,127,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its position in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the 4th quarter worth approximately $37,000. Larson Financial Group LLC grew its holdings in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after acquiring an additional 317 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after acquiring an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Remove Ads

Moderna Trading Down 2.6 %

Shares of Moderna stock traded down $0.87 during trading hours on Thursday, reaching $32.45. 3,765,409 shares of the company's stock were exchanged, compared to its average volume of 6,572,038. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The firm has a market capitalization of $12.52 billion, a price-to-earnings ratio of -3.50 and a beta of 1.86. The company has a fifty day moving average of $35.31 and a 200-day moving average of $46.45.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a report on Friday, February 14th. Bank of America lowered their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Finally, Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price on the stock. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna currently has an average rating of "Hold" and an average price target of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.